Acquisition
Jul 2025Persephoni BioPartners said it launched Telos Therapeutics via a strategic acquisition of key assets, data packages, and early-stage programs from Entelexo Biotherapeutics.
SourceCreating a New Class of Drugs to Address Incurable Autoimmune Diseases
Company research
Public company, workplace, funding, and market signals
Overview
Entelexo Biotherapeutics is an Irvine-based biotech developing engineered exosome therapeutics for complex autoimmune diseases using a proprietary platform that targets multiple cell types and aims to move beyond single-cytokine treatments.
Primary product
Engineered exosome-based therapeutics for autoimmune disease
Founded
2020
Headquarters
Irvine, California, United States
Team size
1-10
Industry
Pharmaceutical Manufacturing
Sub-industry
Exosome therapeutics / drug discovery
Offices
5270 California Ave, Ste 300, Irvine, CA 92617-3231
Open Positions
0 jobs at Entelexo Biotherapeutics
No open positions
Check back later for new openings